Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
03. August 2022 09:00 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first...
Isracann Biosciences Renews Leadership to Meet Changing Demands
15. April 2022 08:30 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its...
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
24. Februar 2022 16:09 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on...
Isracann Signs LOI to Acquire Natural Health Medicine Developer
23. Februar 2022 08:30 ET
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on...